肺功能与基线临床特征对系统性硬化症相关间质性肺病患者报告结局的影响
SENSCIS®试验的事后分析汇总治疗组,评估基线和第52周时SSc-ILD严重程度与患者报告结局的关联。第52周时FVC<70%预计值者SGRQ 45.1 vs 34.0(P<0.0001)、FACIT-呼吸困难48.9 vs 44.5(P<0.0001)、HAQ-DI 0.7 vs 0.6(P<0.0228)、SHAQ VAS呼吸问题3.6 vs 2.6(P<0.0001),均差于FVC≥70%预计值者。弥漫性皮肤型SSc及基线需吸氧或高分辨率CT纤维化>30%者第52周PRO评分更差。
要点
- 第52周FVC<70%预计值者SGRQ 45.1 vs 34.0(P<0.0001),差于FVC≥70%预计值者。
- 弥漫性皮肤型SSc及基线需吸氧或纤维化>30%者第52周PRO评分更差。
- 1年后FVC改善或恶化>10%者SGRQ等PRO相应改善或恶化,SGRQ症状域P<0.001。
核心结论
- 严重SSc-ILD和肺功能大幅恶化对健康相关生活质量有重要影响。
- 减缓肺功能下降和预防严重SSc-ILD的治疗对保持健康相关生活质量重要。
研究设计与样本
- SENSCIS®试验的事后分析,汇总治疗组,评估基线和第52周PRO测量与SSc-ILD严重程度的关联。
- PRO测量包括圣乔治呼吸问卷(SGRQ)、慢性病治疗功能评估-呼吸困难(FACIT-Dyspnoea)和HAQ-残疾指数(HAQ-DI),并纳入硬皮病HAQ视觉模拟量表(SHAQ VAS)。
- 试验注册号NCT02597933。
主要发现
- 基线和第52周FVC<70%预计值者PRO评分差于FVC≥70%预计值者;第52周SGRQ 45.1 vs 34.0(P<0.0001),FACIT-呼吸困难48.9 vs 44.5(P<0.0001),HAQ-DI 0.7 vs 0.6(P<0.0228),SHAQ VAS呼吸问题3.6 vs 2.6(P<0.0001)。
- 弥漫性皮肤型SSc及其他与SSc-ILD严重程度相关的特征者PRO评分更差。
- 基线需吸氧或高分辨率CT纤维化>30%者第52周PRO评分更差。
- 1年后FVC改善或恶化>10%者SGRQ及其他PRO相应改善或恶化,SGRQ症状域显著(P<0.001)。
关键数值与推荐
- 第52周FVC<70%预计值 vs ≥70%预计值:SGRQ 45.1 vs 34.0(P<0.0001)。
- 第52周FVC<70%预计值 vs ≥70%预计值:FACIT-呼吸困难48.9 vs 44.5(P<0.0001)。
- 第52周FVC<70%预计值 vs ≥70%预计值:HAQ-DI 0.7 vs 0.6(P<0.0228)。
- 第52周FVC<70%预计值 vs ≥70%预计值:SHAQ VAS呼吸问题3.6 vs 2.6(P<0.0001)。
- 1年后FVC改善或恶化>10%者SGRQ症状域变化显著(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The SENSCIS® trial demonstrated a significant reduction of lung function decline in patients with SSc-associated interstitial lung disease (SSc-ILD) treated with nintedanib, but no significant effect on health-related quality of life (HRQoL). To assess whether SSc/SSc-ILD severity and large changes in lung function correlate with HRQoL, a post-hoc analysis of SENSCIS®, aggregating treatment arms, was undertaken. METHODS: Patient-reported outcome (PRO) measures [St. George's Respiratory Questionnaire (SGRQ), Functional Assessment of Chronic Illness Therapy (FACIT)-Dyspnoea, and HAQ-Disability Index (HAQ-DI), incorporating the Scleroderma HAQ visual analogue scale (SHAQ VAS)] at baseline and week 52 were assessed for associations to SSc-ILD severity. RESULTS: At baseline and at week 52, forced vital capacity (FVC) <70% predicted was associated with worse PRO measure scores compared with FVC ≥70% predicted [week 52: SGRQ 45.1 vs 34.0 (P < 0.0001); FACIT-Dyspnoea 48.9 vs 44.5 (P < 0.0001); HAQ-DI 0.7 vs 0.6 (P < 0.0228); SHAQ VAS breathing problems 3.6 vs 2.6 (P < 0.0001)]. Patients with diffuse cutaneous SSc and other characteristics associated with SSc-ILD severity had worse PRO measure scores. Patients requiring oxygen or with >30% fibrosis on high-resolution computed tomography at baseline demonstrated worse PRO measure scores at week 52. After 1 year, patients with a major (>10%) improvement/worsening in FVC demonstrated corresponding improvement/worsening in SGRQ and other PRO measures, significant for the SGRQ symptom domain (P < 0.001). CONCLUSION: Severe SSc-ILD and major deteriorations in lung function have important impacts on HRQoL. Treatments that slow lung function decline and prevent severe SSc-ILD are important to preserve HRQoL. TRIAL REGISTRATION: clinicaltrials.gov, www.clinicaltrials.gov, NCT02597933.
引用
- Kreuter M, Hoffmann-Vold AM, Matucci-Cerinic M, et al. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2023. PMID: 35640959. doi:10.1093/rheumatology/keac325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。